FORMULATION AND CHARACTERIZATION FAST DISSOLVING ORAL WAFERS OF AN ANTIMIGRAINE DRUG RIMEGEPANT
Damyanti Kumari, Sweety Tiwari, Akhlesh Kumar Singhai
ABSTRACT
The present study focuses on the formulation and evaluation of fast-dissolving oral wafers of Rimegepant, an anti-migraine drug aimed at providing rapid relief in acute migraine conditions. Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, suffers from poor water solubility and a slower onset when administered orally in conventional forms. To overcome these limitations, oral wafers were developed using suitable film-forming agents and superdisintegrants to ensure rapid disintegration and drug release in the oral cavity without the need for water. Nine formulations (F1–F9) were prepared and evaluated for physical appearance, weight variation, surface pH, folding endurance, moisture content, drug content, disintegration time, and in-vitro drug release. Among all, formulation F7 demonstrated the best characteristics, with a disintegration time of 15 ± 2 seconds, drug content of 99.45 ± 0.15%, and cumulative drug release of 98.85% within 5 minutes. These results suggest that fast-dissolving oral wafers of Rimegepant could serve as a patient-friendly, effective, and fast-acting alternative for migraine management.
[Full Text Article]